SCHEMBL5651271

SCHEMBL5651271

Cc1cccc2[nH]c(-c3ccc(C(=O)NN4CCCCC4)cc3F)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 8/20 0.50
GAA P10253 8/20 0.50
SI P14410 8/20 0.50
MGAM2 Q2M2H8 8/20 0.50
DHODH Q02127 3/20 0.42
HPSE Q9Y251 2/20 0.41
APLNR P35414 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PARP1 P09874 4/20 0.41
PARP2 Q9UGN5 2/20 0.41
MAP4K4 O95819 1/20 0.40
CSF1R P07333 1/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650808 0.91 MGAM (0.48) MGAMGAASIMGAM2HPSE
SCHEMBL5652484 0.89 HPSE (0.48) MGAMGAASIMGAM2HPSE
SCHEMBL5650016 0.87 MGAM (0.48) MGAMGAASIMGAM2DHODH
SCHEMBL5652928 0.84 HPSE (0.53) MGAMGAASIMGAM2HPSE
SCHEMBL5651334 0.84 HPSE (0.57) MGAMGAASIMGAM2DHODH
SCHEMBL5650901 0.83 AURKA (0.45) GAAHPSEKDM4EALDH1A1HPGD
SCHEMBL5653971 0.81 AMY1A (0.42)
SCHEMBL5652478 0.80 HDAC6 (0.48) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5650995 0.78 PRSS12 (0.47) HPGD
SCHEMBL5653369 0.78 CBFB (0.44) DHODHMAP4K4CSF1RPIM1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 MGAM 3224/4885GAA 4139/4885SI 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.